A costly therapeutic dilemma in tophaceous gout: is etanercept or rasburicase preferable?

Ann Rheum Dis. 2005 Mar;64(3):516; author reply 516.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Comment

MeSH terms

  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Gouty / drug therapy*
  • Etanercept
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Infant, Newborn
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Recombinant Proteins / therapeutic use
  • Treatment Outcome
  • Urate Oxidase / therapeutic use*

Substances

  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Recombinant Proteins
  • rasburicase
  • Urate Oxidase
  • Etanercept